The European Union has decided to shorten the exclusivity period for new drugs, allowing cheaper generic versions to enter the market a year earlier. This move aims to reduce healthcare costs and increase competition in the pharmaceutical industry. The change is expected to impact pharmaceutical companies' revenue and profitability.